4.8 • 1.4K Ratings
🗓️ 13 June 2022
⏱️ 47 minutes
🧾️ Download transcript
Click on a timestamp to play from that location
0:00.0 | Hi everyone, welcome back to another HPV episode of Behind the Knife, where your HPV |
0:27.2 | team from Brook Army Medical Center and William Beaumont and El Paso. Today's episode will be |
0:32.5 | complimentary to our last episode on Metacranus colorectal liver mitts. So if you hadn't had a |
0:37.2 | chance to check that one out, we'd highly suggest you listen to that one first. But we're extremely |
0:41.8 | excited to bring you this journal club episode today, discussing mutations in colorectal liver |
0:46.3 | metastases. We'll have a team discussion of the article first followed by an interview at the |
0:51.2 | April IHPBA meeting with one of the foremost experts in the field and senior author, Dr. |
0:56.4 | Jean Nicolas Voté. So the specific article we'll be discussing is called genomic sequencing and |
1:02.0 | insight into clinical heterogeneity and prognostic pathway genes in patients with metastatic colorectal |
1:07.4 | cancer. And the first author was Dr. Kawaguchi and the senior author, as we mentioned, was Dr. Jean |
1:13.6 | Nicolas Voté. Dr. Nelson, do you want to give us a kind of bird's eye view of the article and the |
1:20.0 | intent behind the article to get us started? So I think to introduce this article, the best way to |
1:25.3 | think about this is that right now metastatic colon cancer is classified into a single risk group |
1:31.8 | of stage four patients. Taken together, those patients have a five-year overall survival around 15%. |
1:39.2 | But we know that amongst these patients, there's a wide range of clinical behaviors with patients |
1:45.7 | that undergo a resection of liver-only colorectal metastases having survival up to 40 to 60%. |
1:53.2 | And what we've come to learn is that these tumors are genomically heterogeneous. They have a wide |
2:00.4 | range of mutations within them. And we've been able to start to approve data on the different |
2:08.5 | mutations that are occurring within these metastases amongst different patients. And now with |
2:14.1 | getting all of this data together, and the Anderson in this paper was able to evaluate the frequency |
2:20.7 | of these mutations and really look at mutations within these signaling pathways, how they are |
2:28.3 | or contribute to prognostication amongst these stage four patients. So with that, Beth, |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Behind The Knife: The Surgery Podcast, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Behind The Knife: The Surgery Podcast and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2025.